NASDAQ:CAPR - Capricor Therapeutics, Inc.
$0.44
 $0.02
+4.22%
2:35PM EDT
2019-02-15
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CAPR     avg for
industry  
  avg for
sector  
42 stocks weight:  9. 70   0. 00   0. 00  
42 stocks rank:  3. 92 K 1. 86 K 1. 09 K
# analyst opinions:  1. 00   14. 92   14. 43  
mean recommendation:  2. 50   1. 91   1. 93  

quick ratio:  5. 62   5. 37   1. 81  
current ratio:  6. 07   5. 69   2. 19  

target price low:  0. 35   88. 97   117. 82  
target price avg:  0. 35   115. 19   141. 96  
target price high:  0. 35   143. 40   163. 16  
1-yr high:  1. 88   124. 30   142. 77  
last close:  0. 42   101. 85   127. 84  
50-day avg:  0. 54   98. 27   122. 46  
200-day avg:  1. 00   99. 72   122. 70  
1-yr low:  0. 32   78. 19   100. 16  
volume:  147. 91 K 2. 38 M 4. 64 M
50-day avg volume:  357. 30 K 3. 31 M 4. 94 M
200-day avg volume:  219. 64 K 3. 23 M 4. 28 M

1-day return:  -2. 33 % 0. 22 % 0. 48 %
this week return:  -8. 70 % 1. 77 % 2. 01 %
12-wk return:  -50. 00 % 6. 56 % 3. 33 %
52-wk return:  -77. 95 % -2. 23 % 14. 35 %

enterprise value (EV):  2. 99 M 55. 17 B 104. 51 B
market cap:  13. 31 M 49. 01 B 96. 46 B
EBITDA:  -15. 15 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -0. 20   -91. 79   2. 29  
enterprise/revenue (EV/R):  1. 99   29. 84   23. 39  
total revenue:  1. 50 M 11. 28 B 40. 22 B
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  373. 95 K 2. 37 B 3. 58 B

shares outstanding:  31. 07 M 607. 99 M 1. 22 B
shares:  19. 97 M 605. 53 M 1. 15 B
shares short:  741. 77 K 11. 62 M 12. 55 M
shares short prior month:  845. 16 K 11. 95 M 13. 44 M
short ratio:  1. 32   4. 82   3. 10  
short % of float:  4. 42 % 6. 19 % 2. 82 %
total cash/share:  0. 33   12. 02   11. 46  
total cash:  10. 37 M 7. 41 B 7. 37 B
free cash flow:  -8. 39 M 95. 99 M 2. 04 B
operating cash flow:  -12. 76 M 164. 74 M 3. 04 B

book value:  0. 23   14. 43   28. 26  
price/book:  1. 85   -1. 57   -2. 97  
gross profits:  -8. 10 M 8. 28 B 18. 09 B
operating margins:  -1020. 73 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  24. 95 % 6. 57 % 9. 92 %
gross margins:  0. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  -23. 19 % --- ---
1-yr mean volatility:  -0. 50 % 0. 01 % 0. 06 %

1-yr EPS:  0. 01   3. 03   4. 09  
forward EPS:  -0. 50   4. 33   6. 99  
P/E:  38. 18   6. 11   26. 91  
forward P/E:  -0. 90   8. 38   10. 48  
PE/G:  -1. 27   0. 37   5. 61  
growth:  -30. 00 % 683. 72 % 104. 79 %
earnings high:  -0. 15   1. 27   1. 66  
earnings avg:  -0. 16   1. 01   1. 53  
earnings low:  -0. 17   0. 76   1. 40  
revenue high:  230. 00 K 2. 86 B 11. 19 B
revenue avg:  120. 00 K 2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -68. 25 % -3. 27 % 3. 81 %
return on equity:  27. 60 % 107. 48 % 27. 82 %
revenue growth:  -30. 00 % 648. 36 % 97. 70 %
revenue/share:  0. 05   14. 68   59. 83  

beta (1yr vs S&P500):  0. 70   1. 21   0. 93  
sharpe (1yr):  -1. 60   0. 06   0. 98  

held % insiders:  35. 68 % 6. 46 % 3. 21 %
held % institutions:  7. 06 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : CAPR
.    + 0.659 =         0.659 :: INITIAL WEIGHT
.   + 709.03 =       709.689 :: inverse volume-to-price addition
.   + 306.97 =       1016.66 :: spline projection addition
.  - 205.764 =       810.895 :: poor performance penalty
.    x 0.515 =       417.677 :: one-year gains+dividend factor
.    x 0.821 =       342.925 :: 13 weeks' performance factor
.    x 1.492 =       511.811 :: industry recommendation factor
.    x 1.642 =       840.186 :: symbol recommendation factor
.    x 1.067 =       896.309 :: EV/R factor
.    x 0.993 =       890.192 :: return on assets factor
.    x 1.527 =       1359.07 :: return on equity factor
.    x 0.997 =      1354.993 :: revenue growth factor
.    x 2.934 =      3974.916 :: current ratio factor
.    x 1.103 =      4384.046 :: quick ratio factor
.    x 1.326 =      5812.087 :: short ratio factor
.    x 2.019 =     11731.711 :: price-to-book factor
.    x 2.972 =     34864.869 :: P/E weight
.    x 0.941 =      32824.96 :: PE/G factor
.    x 1.524 =     50028.979 :: beta factor
.    x 0.393 =     19643.281 :: sharpe factor
.    x 0.959 =     18841.347 :: target low factor
.    x 0.928 =     17477.985 :: target mean factor
.    x 0.959 =     16764.449 :: target high factor
.    x 1.066 =     17864.412 :: industry 12-weeks return
.    x 0.882 =     15760.235 :: "drift" penalty 2 days ago
.     x 0.97 =     15292.086 :: overall "drift" factor
.    x 0.999 =     15275.745 :: largest single-day jump factor
.     x 0.06 =       911.441 :: low price factor
.      x 1.0 =       911.502 :: factor hist industry gain for week 06
.   cubeRoot =         9.696 :: reduced for readability
.                      9.696 :: FINAL WEIGHT for NASDAQ:CAPR


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org